根据最近一项大型多数据库分析的结果，携带KRAS G12C突变的结直肠癌和胰腺导管腺癌通常携带其他可能与KRAS G12C抑制剂耐药相关的遗传改变，尽管之前没有接受过这种治疗。 一项大规模多数据库分析的最新结果显示，携带KRAS G12C突变的结直肠癌和胰腺导管腺癌 ...

近日，信达生物制药的肺癌靶向药氟泽雷塞片（GFH925/IBI351，商品名：达伯特）正式被中国国家药品监督管理局（NMPA）批准 ...

一直以来，KRAS都被称作“不可成药靶点”，直到KRAS G12C抑制剂的出现，才打破了这一“魔咒”。受此鼓舞，更多药企开始将目光投向KRAS的其他突变 ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

Among patients with KRAS G12C mutations, candidate primary resistance mutations were detected in many patients with colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), which may ...

Bottom line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...

and may explain the limited efficacy of KRAS G12C inhibitor monotherapy,” Xie said. “Their presence also indicates the higher level of tumor heterogeneity in colorectal and pancreatic cancers, and ...

"These other co-occurring mutations associated with poor prognosis may serve as cellular adaptation and primary resistance mechanisms, and may explain the limited efficacy of KRAS G12C inhibitor ...

TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage biopharmaceutical company ...

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

Bottom Line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...